← Back to Clinical Trials
Recruiting NCT05884983

NCT05884983 Screening Effect of Dual-energy CT Combined With Nasopharyngeal Endoscopy for Screening Nasopharyngeal Carcinoma

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05884983
Status Recruiting
Phase
Sponsor Zhongshan People's Hospital, Guangdong, China
Condition Nasopharyngeal Carcinoma
Study Type OBSERVATIONAL
Enrollment 12,000 participants
Start Date 2023-02-01
Primary Completion 2026-12-31

Trial Parameters

Condition Nasopharyngeal Carcinoma
Sponsor Zhongshan People's Hospital, Guangdong, China
Study Type OBSERVATIONAL
Phase N/A
Enrollment 12,000
Sex ALL
Min Age 30 Years
Max Age 69 Years
Start Date 2023-02-01
Completion 2026-12-31
Interventions
participants will undergo dual-energy CT and endoscopy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

All participants will be tested for EBV-related biomarkers, including EBNA1-IgA, VCA-IgA, and BNLF2b total antibody (P85-Ab), and participants with high serologic risk will be selected based on serologic test results, and dual-energy CT will be performed first for high-risk screening subjects, and dual-energy CT will be performed first for the high-risk group to record dual-energy CT examinations of those suspected of nasopharyngeal carcinoma, and then endoscopy was performed on the high-risk group to record those suspected of nasopharyngeal carcinoma under endoscopy, and finally biopsies were taken for positive lesion sites indicated by dual-energy CT and suspicious lesion sites found by endoscopy to clarify the diagnosis.

Eligibility Criteria

Inclusion Criteria: * Subject residents in Zhongshan City * Subject has no medical record of nasopharyngeal carcinoma * Subject is able to comprehend, sign, and date the written informed consent document to participate in the study * Subject has psychical condition and well consciousness, and also accept and cooperate with the follow-up of this study Exclusion Criteria: * Subject has heavy cardiovascular, liver or kidney disease * Subject has contraindications to nasopharyngeal endoscopy * Subject has contrast media allergy

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology